Renaissance Technologies LLC trimmed its position in Sana Biotechnology, Inc. (NASDAQ:SANA – Free Report) by 14.2% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 1,451,200 shares of the company’s stock after selling 239,916 shares during the quarter. Renaissance Technologies LLC’s holdings in Sana Biotechnology were worth $4,179,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of the company. Rockefeller Capital Management L.P. increased its stake in Sana Biotechnology by 74.3% during the 4th quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company’s stock valued at $39,000 after purchasing an additional 4,088 shares in the last quarter. LRI Investments LLC bought a new position in shares of Sana Biotechnology in the fourth quarter valued at $41,000. Jacobi Capital Management LLC acquired a new position in shares of Sana Biotechnology during the fourth quarter valued at about $41,000. Mercer Global Advisors Inc. ADV bought a new stake in shares of Sana Biotechnology during the third quarter worth about $36,000. Finally, Cibc World Markets Corp bought a new stake in shares of Sana Biotechnology during the fourth quarter worth about $44,000. 88.23% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Several brokerages recently weighed in on SANA. Weiss Ratings raised shares of Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 23rd. Wedbush boosted their price objective on Sana Biotechnology from $6.00 to $7.00 and gave the stock an “outperform” rating in a report on Tuesday, April 14th. Wall Street Zen downgraded Sana Biotechnology from a “hold” rating to a “sell” rating in a research note on Monday, July 20th. Finally, Rodman & Renshaw initiated coverage on Sana Biotechnology in a report on Monday, May 11th. They issued a “buy” rating and a $16.00 target price on the stock. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Sana Biotechnology currently has a consensus rating of “Moderate Buy” and an average target price of $9.50.
Sana Biotechnology Price Performance
Shares of SANA stock opened at $3.52 on Friday. The firm has a 50-day moving average of $3.30 and a 200-day moving average of $3.49. Sana Biotechnology, Inc. has a one year low of $2.61 and a one year high of $6.55. The company has a market cap of $979.58 million, a P/E ratio of -3.78 and a beta of 2.16.
Sana Biotechnology (NASDAQ:SANA – Get Free Report) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.01. As a group, research analysts expect that Sana Biotechnology, Inc. will post -0.59 earnings per share for the current fiscal year.
Sana Biotechnology Company Profile
Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.
The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.
Featured Stories
- Five stocks we like better than Sana Biotechnology
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Want to see what other hedge funds are holding SANA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sana Biotechnology, Inc. (NASDAQ:SANA – Free Report).
Receive News & Ratings for Sana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
-B3.png){kind=small}
